Tucusituzumab
|
WikiDoc Resources for Tucusituzumab |
|
Articles |
|---|
|
Most recent articles on Tucusituzumab Most cited articles on Tucusituzumab |
|
Media |
|
Powerpoint slides on Tucusituzumab |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tucusituzumab at Clinical Trials.gov Trial results on Tucusituzumab Clinical Trials on Tucusituzumab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tucusituzumab NICE Guidance on Tucusituzumab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tucusituzumab Discussion groups on Tucusituzumab Patient Handouts on Tucusituzumab Directions to Hospitals Treating Tucusituzumab Risk calculators and risk factors for Tucusituzumab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tucusituzumab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Tucusituzumab is a humanized monoclonal antibody used to treat cancers of the epithelial origin. It binds to interleukin-2.